COVID-19

Abstract Lipid nanoparticles (LNPs) have demonstrated their therapeutic potential as safe and effective drug delivery systems for nucleic acids during the COVID-19 pandemic. However, one of the main challenges during technical CMC (Chemistry, Manufacturing, and Controls) development is their…
Read More...

Abstract Objective: Many severe acute respiratory infections are caused by viral pathogens, and viruses are responsible for a large number of deaths worldwide. Among the most common respiratory viruses are the influenza A virus (IAV) and, more recently, the SARS-CoV-2 that emerged in 2019 and…
Read More...

Background The lipid self-emulsifying system has been advanced as a promising delivery vehicle for improving the solubility and bioavailability of artemether and lumefantrine. However, the observed kinetic instability (propensity of lumefantrine to rapid crystallisation from nano-scale droplets) in…
Read More...

A library of 16 lipid nanoparticle (LNP) formulations with orthogonally varying lipid molar ratios was designed and synthesized, using polyadenylic acid  as a model for mRNA, to explore the effect of lipid composition in LNPs on (i) the initial size of the resultant LNPs and encapsulation efficiency…
Read More...

The upper airways represent the point of entrance from where Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection spreads to the lungs. In the present work, α-tocopheryl-polyethylene-glycol succinate (TPGS) micelles loaded with cyclosporine A (CSA) were developed for nasal…
Read More...

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a threat to human beings' health. However, there is still a lack of effective specific antiviral drugs for SARS-CoV-2 at present, which calls for the exploitation of new potent and safe therapeutic agents.…
Read More...

Vaccines have a tremendous impact on public health, and their importance has been emphasized by the COVID-19 pandemic. Here, we provide an overview of the current state of research and development (R&D) on prophylactic vaccine candidates for infectious diseases globally. Technology platforms…
Read More...

Nanomedicines are complex drugs where components that have typically been regarded as excipients may now be considered part of the active ingredient. The distinction between the active ingredient and excipients for nanomedicines has important consequences for regulatory review and product…
Read More...

Ever since the development of the first vaccine, vaccination has had the great impact on global health, leading to the decrease in the burden of numerous infectious diseases. However, there is a constant need to improve existing vaccines and develop new vaccination strategies and vaccine platforms…
Read More...

Neutralising monoclonal antibody (mAb) is an important weapon in our arsenal for combating respiratory viral infections. However, the effectiveness of neutralising mAb has been impeded by the rapid emergence of mutant variants. Early administration of broad-spectrum mAb with improved delivery…
Read More...